- June 23, 2010
- Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology.
- >> more
- April 20, 2010
- Mersana Therapeutics Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure.
- >> more
|
|
Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.
|